New York Senate Bill S09523

New York 2025-2026 Regular Session

• Introduced: 3/19/26
• Refer: 3/19/26

Caption

Provides for coverage for treatments to slow the progression of Alzheimer's disease and related dementias.

Summary

S09523 would require a broad set of New York health coverage arrangements to pay for medically necessary diagnostic testing and FDA-approved treatments or medications used to slow the progression of Alzheimer’s disease and other related dementias. The mandate applies to individual, group, blanket, and certain nonprofit health plans, as well as to Medicaid coverage under the social services law. Coverage must be provided when prescribed by a physician licensed in New York and used in accordance with the FDA label. The bill also bars insurers and Medicaid from applying step therapy to these Alzheimer’s and dementia treatments. In practical terms, that means a patient could not be forced to try and fail other drugs first before accessing an FDA-approved therapy covered by the bill. The measure would take effect on January 1 following enactment and would apply to policies and contracts issued, renewed, modified, altered, or amended on or after that date.

Impact

The bill would amend sections of the Insurance Law and Social Services Law to create a new coverage mandate for Alzheimer’s disease and related dementia care across most major health insurance products and Medicaid. It would expand required benefits to include diagnostic testing and FDA-approved treatment options intended to slow disease progression, while prohibiting step therapy for those services. Insurers, health service corporations, hospital service corporations, and Medicaid would need to align coverage policies with the new statutory requirements for applicable plans and contracts.

Sentiment

The bill’s stated purpose and structure suggest a strongly supportive posture toward expanding access to Alzheimer’s and dementia treatments. Although no committee transcript or vote record is provided, the measure is framed as a patient-access and coverage mandate, indicating a consumer- and caregiver-oriented policy approach. The absence of recorded opposition in the provided materials means there is no documented legislative debate here, but the inclusion of a step-therapy prohibition suggests the bill is designed to address barriers to timely treatment.

Contention

The main likely point of contention is cost and utilization management: insurers and public payers may object to a mandated benefit that requires coverage of potentially expensive new therapies and diagnostic testing. Another likely issue is the ban on step therapy, which limits insurer control over treatment sequencing and may be viewed as reducing prior authorization tools. Supporters would likely emphasize earlier access to FDA-approved Alzheimer’s treatments and reduced administrative barriers for patients and families affected by dementia.